Prostate cancer, the most common cancer diagnosed in men after skin cancer, affects about one in six American men. It ranks second only to lung cancer in cancer deaths in men.
Yet screening for and treating this disease remain challenging. Current technology limits doctors’ ability to precisely determine an individual’s prostate cancer risk and life expectancy once diagnosed with the disease.
Masonic Cancer Center (MCC) scientists explored these complexities at the 2010 Masonic Symposium in November. The forum highlighted progress made at the MCC in areas supported by the Masons of Minnesota.
Attendees asked questions of scientists at the forefront of cancer research, while MCC members heard firsthand the concerns of individuals and families who are dealing with cancer.
